Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD von Celli, Bartolome, MD, FCCP, Crater, Glenn, MD, FCCP, Kilbride, Sally, MSc, Mehta, Rashmi, PhD, Tabberer, Maggie, MSc, Kalberg, Chris J., PhD, Church, Alison, MD

Volltext

Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD von O'Donnell, Denis E., Sciurba, Frank, Celli, Bartolome, Mahler, Donald A., Webb, Katherine A., Kalberg, Chris J., Knobil, Katharine

Volltext

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study von Kerwin, Edward M, Kalberg, Chris J, Galkin, Dmitry V, Zhu, Chang-Qing, Church, Alison, Riley, John H, Fahy, William A

Volltext

Daily variation in lung function in COPD patients with combined albuterol and ipratropium: Results from a 4-week, randomized, crossover study von Singh, Dave, Zhu, Chang-Qing, Sharma, Sanjay, Church, Alison, Kalberg, Chris J

Volltext

Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study von Riley, John H, Kalberg, Chris J, Donald, Alison, Lipson, David A, Shoaib, Muhammad, Tombs, Lee

Volltext

Dose-Related Efficacy of GSK573719: A Long-Acting Muscarinic Receptor Antagonist (LAMA) With Sustained 24-Hour Activity in COPD von Donohue, James, MD, Anzueto, Antonio, MD, Brooks, Jean, MS, Mehta, Rashmi, PhD, Kalberg, Chris, PhD, Crater, Glenn, MD

Volltext

Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis von Halpern, Michael T., Schmier, Jordana K., Van Kerkhove, Maria D., Watkins, Michael, Kalberg, Chris J.

Volltext

Population Pharmacokinetics of Inhaled Umeclidinium and Vilanterol in Patients with Chronic Obstructive Pulmonary Disease von Goyal, Navin, Beerahee, Misba, Kalberg, Chris, Church, Alison, Kilbride, Sally, Mehta, Rashmi

Volltext

Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial von Kalberg, Chris, O’Dell, Dianne, Galkin, Dmitry, Newlands, Amy, Fahy, William A.

Volltext

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial von Busse, William, Raphael, Gordon D., Galant, Stanley, Kalberg, Chris, Goode-Sellers, Stacey, Srebro, Sharon, Edwards, Lisa, Rickard, Kathy

Volltext

Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study von Celli, Bartolome, Crater, Glenn, Kilbride, Sally, Mehta, Rashmi, Tabberer, Maggie, Kalberg, Chris J, Church, Alison

Volltext

PREVALENCE OF COPD-DEFINED AIRFLOW OBSTRUCTION IN UNDIAGNOSED PRIMARY CARE SUBJECTS WITH SYMPTOMS OF CHRONIC BRONCHITIS von Yawn, Barbara, Mannino, David, Littlejohn, Thomas, Ruoff, Gary, Emmett, Amanda, Kalberg, Chris, Raphiou, Ibrahim, Crater, Glenn D.

Volltext

A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING THE EFFECT OF FLUTICASONE/SALMETEROL 250/50 TO SALMETEROL ON COPD EXACERBATIONS IN PATIENTS WITH COPD von Ferguson, Gary, Anzueto, Antonio, Fei, Richard, Emmett, Amanda, Crater, Glenn, Knobil, Kate, Kalberg, Chris

Volltext

A Comparison of Patient Perceived Improvement in Symptoms After Initiating Therapy with Either Advair Diskus (fluticasone propionate/salmeterol) 250/50 or Ipratropium/Albuterol von Knobil, Katharine, Merchant, Kunal, Kalberg, Chris, Emmett, Amanda, Cicale, Michael

Volltext

Maintenance of Bronchodilator Response for Advair Diskus 250/50 (Fluticasone Propionate/Salmeterol) but not Ipratropium/Albuterol in Patients with COPD von Knobil, Katharine, Kalberg, Chris, Merchant, Kunal, Emmett, Amanda, Cicale, Michael

Volltext

Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting β2-Agonists alone von CALHOUN, William J, NELSON, Harold S, NATHAN, Robert A, PEPSIN, Pamela J, KALBERG, Chris, EMMETT, Amanda, RICKARD, Kathleen A, DORINSKY, Paul

Volltext

USING DISTRIBUTION-BASED STANDARD ERROR OF MEASUREMENT (SEM) METHOD TO DETERMINE MINIMAL IMPORTANT DIFFERENCE (MID) FOR THE SYMPTOM STATUS INDEX (SSI) von Borker, Rohit D., Watkins, Michael, Knobil, Kate, Emmett, Amanda, Kalberg, Chris

Volltext

Efficacy and Safety of Low-Dose Fluticasone Propionate Compared With Montelukast for Maintenance Treatment of Persistent Asthma von MELTZER, ELI O., LOCKEY, RICHARD F., FRIEDMAN, BRUCE F., KALBERG, CHRIS, GOODE-SELLERSO, STACEY, SREBRO, SHARON, EDWARDS, LISA, RICKARD, KATHLEEN

Volltext

Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma von MELTZER, Eli O, LOCKEY, Richard F, FRIEDMAN, Bruce F, KALBERG, Chris, GOODE-SELLERS, Stacey, SREBRO, Sharon, EDWARDS, Lisa, RICKARD, Kathleen

Volltext

In Reply: Salmeterol and Tolerance von Rosenthal, Richard R., Kalberg, Chris

Volltext